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ABSTRACT  46 
Background 47 
Atopic eczema is a common and debilitating condition associated with depression 48 
and anxiety, but the nature of this association remains unclear.  49 
Objective 50 
To explore the temporal relationship between atopic eczema and new 51 
depression/anxiety.  52 
Methods 53 
A matched cohort study using routinely-collected data from the UK Clinical Practice 54 
Research Datalink, linked to hospital admissions data. We identified adults with 55 
atopic eczema (1998-2016) using a validated algorithm, and up to five individuals 56 
without atopic eczema matched on date of diagnosis, age, sex and general practice. 57 
We estimated the hazard ratio (HR) for new depression/anxiety using stratified Cox 58 
regression to account for age, sex, calendar period, Index of Multiple Deprivation, 59 
glucocorticoid treatment, obesity, smoking and harmful alcohol use. 60 
Results 61 
We identified 526,808 adults with atopic eczema who were matched to 2,569,030 62 
without. Atopic eczema was associated with increased incidence of new depression 63 
(HR 1.14; 99% confidence interval [CI] 1.12-1.16), and anxiety (HR 1.17; 99% CI 64 
1.14-1.19). We observed a stronger effect of atopic eczema on depression with 65 
increasing atopic eczema severity (HR [99% CI] compared to no atopic eczema: mild 66 
1.10 [1.08-1.13]; moderate 1.19 [1.15-1.23]; severe 1.26 [1.17-1.37]). A dose-67 
response association, however, was less apparent for new anxiety diagnosis (HR 68 
[99% CI] compared to no atopic eczema: mild 1.14 [1.11-1.18]; moderate 1.21 [1.17-69 
1.26]; severe 1.15; [1.05-1.25]). 70 
Conclusions 71 
Adults with atopic eczema are more likely to develop new depression and anxiety. 72 
For depression, we observed a dose-response relationship with atopic eczema 73 
severity.   74 
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HIGHLIGHTS BOX  91 
What is already known about this topic? 92 
Atopic eczema is a common debilitating skin condition. An association between 93 
atopic eczema and common mental disorders is well-documented, but its nature and 94 
temporal direction remain unclear. 95 
What does this article add to our knowledge? 96 
Individuals affected with atopic eczema are more likely to develop new depression 97 
(14% increased incidence) and anxiety (17% increased incidence). The observed 98 
dose-response relationship between atopic eczema severity and depression 99 
supports a causal mechanism for the association. 100 
How does this study impact current management guidelines? 101 
Recent atopic eczema guidelines comment briefly on the influence of psychological 102 
and emotional factors on the clinical course of atopic eczema. Our findings suggest 103 
that depression and anxiety should be addressed explicitly in updated guidelines.  104 
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INTRODUCTION 105 
Atopic eczema (eczema, atopic dermatitis) is a chronic relapsing inflammatory skin 106 
disease. It can cause intense itching and discomfort. Itch and disfiguring lesions 107 
result in sleeplessness and social embarrassment, impairing the quality of life of both 108 
sufferers and their families.1,2 Atopic eczema is common (20% of children and up to 109 
10% of adults in developed countries) and is a major cause of years lost due to 110 
disability.2–4 Emerging evidence suggests that biologic agents, an effective treatment 111 
modality for severe atopic eczema,2,5,6 may also reduce symptoms of depression 112 
and anxiety among people with atopic eczema.7 113 
Mental health disorders are one of the leading causes of disability worldwide,8 with 114 
depression and anxiety together accounting for over half of that burden.9 115 
Depression, manifesting as loss of interest and enjoyment in ordinary things and 116 
experiences, affects approximately 4.4% of the global population; anxiety disorders, 117 
characterised by excessive fear, anxiousness, or avoidance of perceived threats, 118 
affect approximately 3.6%.10 Both depression and anxiety are associated with 119 
increased morbidity and mortality.11–15 Atopic eczema has been shown to be 120 
associated with common mental disorders (depression and anxiety) and suicidality in 121 
cross-sectional studies that have frequently relied on self-reported exposures and 122 
outcomes.16–25 Individuals with atopic eczema may be more likely to experience 123 
depression and anxiety through the effects of itch and discomfort, disfigurement, and 124 
perceived social-stigmatisation;26–28 additionally, poor sleep related to atopic eczema 125 
may increase the risk of mental illness.29,30 Inflammatory mediators in atopic eczema 126 
could also contribute to the development of depression.22,31 However, those with 127 
depression and anxiety could also be more likely to consult for a physical condition 128 
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such as atopic eczema. As longitudinal evidence is scarce and conflicting, the 129 
temporality of any association between atopic eczema and depression and anxiety, 130 
and whether the relationship changes with increasing atopic eczema severity, 131 
remains unclear.32–34 132 
Insight into the temporal relationship between atopic eczema and depression/anxiety 133 
could guide the clinical approach to this vulnerable group with visible and potentially 134 
stigmatising skin disease. Atopic eczema is common, so if people with atopic 135 
eczema are indeed at increased risk of new-onset depression or anxiety, then this 136 
would suggest: 1) a major population impact; 2) a potential role for targeted mental 137 
health screening for individuals with atopic eczema; and 3) the possibility of mental 138 
health modification through improved atopic eczema control (for example, using new 139 
biologic agents). Therefore, we aimed to investigate the association between atopic 140 
eczema and newly-diagnosed depression and anxiety, and whether any association 141 
increased with increasing atopic eczema severity through a longitudinal analysis of 142 
UK primary care electronic health record data.   143 
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METHODS 144 
Study design and setting 145 
We conducted a cohort study, using routinely-collected primary care electronic 146 
health record data from practices contributing to the UK Clinical Practice Research 147 
Datalink (CPRD), and linked hospital admissions data from the Hospital Episode 148 
Statistics (HES) database. The CPRD covers approximately 7% of the UK 149 
population, is broadly representative of the general population and includes 150 
demographic information, diagnoses, prescriptions and secondary care referrals.35 151 
Diagnoses are recorded in the CPRD using Read codes,36 and have been 152 
demonstrated to be valid.37,38 The CPRD assures high-quality data through 153 
algorithmic analysis of gaps in data entry and deaths recorded by each practice.35 154 
HES includes data on all the National Health Service funded inpatient hospital stays 155 
in England since 1997, including diagnoses recorded using the International 156 
Classification of Diseases, 10th revision coding system (ICD-10).39 Linkage to HES 157 
data is available in approximately 80% of English CPRD practices. The study period 158 
was from 02/01/1998-31/03/2016.  159 
Study population 160 
Individuals with atopic eczema and disease severity 161 
Atopic eczema diagnosis was based on a validated algorithm (positive predictive 162 
value of 82%) requiring a record of at least one diagnostic code for atopic eczema 163 
and at least two records for atopic eczema therapy.40 Systemic glucocorticoids were 164 
not included in the validated algorithm to identify atopic eczema, and their use is 165 
generally discouraged.41 (Text E1). Other inclusion criteria were: adults aged 18 166 
years and over; eligible for HES linkage; registered with a CPRD practice meeting 167 
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CPRD patient- and practice-level quality control standards; and contribution of valid 168 
follow-up time during the study period (02/01/1998-31/03/2016).  169 
To capture the progressive nature of atopic eczema and to avoid immortal-time bias, 170 
atopic eczema severity was modelled as a time-updated variable.42 We categorised 171 
severity into three, mutually exclusive, progressive categories (mild, moderate and 172 
severe) according to recorded atopic eczema therapy.5,43,44 By default, all individuals 173 
with atopic eczema were classified as having mild disease. They could be re-174 
categorised as: 1) moderate atopic eczema if potent topical steroids or calcineurin 175 
inhibitors were prescribed; or 2) severe, if there was a record for a referral to a 176 
dermatologist, or a record for systemic treatment. Individuals with moderate/severe 177 
disease kept their severity category until the end of follow-up and could not be re-178 
categorised as having milder disease (Text E1).  179 
Comparison group of individuals without atopic eczema 180 
Each atopic eczema-exposed individual was matched (without replacement) with up 181 
to five individuals without atopic eczema on sex, age, general practice and calendar 182 
time. Unexposed individuals had no record of a diagnostic code for atopic eczema 183 
(in CPRD or HES) but were required to have at least one year of follow-up in CPRD 184 
as well as meet all other inclusion criteria. To minimise selection bias due to the 185 
exclusion of unmatched individuals and closely adjust for its effects, age was 186 
matched in 15-year strata and used as the underlying time scale for all analysis. To 187 
avoid misclassifying unexposed person-time, individuals could contribute unexposed 188 
person-time until the date of their first record of a diagnostic code for atopic eczema, 189 
regardless of later therapies prescribed. (Figure E1)  190 
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Outcomes 191 
We considered depression and anxiety as separate outcomes, with onset defined as 192 
the date of the first recorded diagnosis in either CPRD or HES (any inpatient hospital 193 
diagnosis). Codes for the depression outcome were those compatible with unipolar 194 
depression,45 and for the anxiety outcome, included those consistent with 195 
generalised anxiety (GAD) and panic disorders. We considered broader definitions of 196 
depression and anxiety in pre-specified sensitivity analyses (Text E2). 197 
Defining follow-up 198 
Individuals entered the cohort at the latest of: practice registration date plus 12 199 
months; the date their practice met CPRD quality control standards; the date an 200 
individual met our atopic eczema diagnosis definition; or the start of the study 201 
(02/01/1998). Individuals without atopic eczema entered the cohort on the same day 202 
as their matched atopic eczema-exposed case. We included a mandatory ‘wash-in’ 203 
period of 12 months prior to cohort entry to assure adequate time to capture true 204 
incident outcome diagnoses, as well as other baseline variables (e.g. body mass 205 
index [BMI], smoking).46  206 
Cohort members were followed until the first of the following events: anxiety or 207 
depression diagnosis (depending on analysis); a diagnosis suggesting an alternative 208 
cause for each outcome (i.e. organic depression or dementia for depression 209 
analyses; obsessive-compulsive disorder or post-traumatic stress disorder anxiety 210 
analyses; and schizophrenia or bipolar disease for both depression and anxiety 211 
analyses); record of a morbidity code for an atopic eczema diagnosis (for the 212 
unexposed group); death date recorded in CPRD; end of registration with practice; 213 
last data collection from practice; or the end of the study (31/03/2016).  214 
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Covariates 215 
Covariate selection was guided by a literature review and construction of a directed 216 
acyclic graph (DAG) to avoid collider bias.47,48 (Text E3, Figure E2, Tables E1 and 217 
E2) Age, calendar period, sex, and level of deprivation (as quintiles of the Index of 218 
Multiple Deprivation score [IMD]), and ethnic group were deemed plausibly 219 
associated with both exposure and outcome, and not on the causal pathway (i.e. 220 
potential confounders). We considered BMI, smoking status, harmful alcohol use, 221 
and high-dose oral glucocorticoid as possible mediators of the association between 222 
atopic eczema and depression/anxiety. The data sources and definitions used to 223 
identify all covariates are detailed in Texts E4 and E5 and morbidity code lists are 224 
available to download (https://doi.org/10.17037/DATA.00000941). 225 
Statistical analysis 226 
We assessed the effect of the atopic eczema exposure on each outcome 227 
(depression or anxiety) using Cox regression stratified by matched set. We included 228 
the covariates used for matching in an initial crude model (implicitly adjusted for sex 229 
and general practice by stratification on matched set, and for age through the 230 
underlying timescale). We then adjusted for the remaining pre-specified potential 231 
confounders (calendar period and IMD) in an adjusted model. Finally, we also further 232 
adjusted for potential mediators of the relationship between atopic eczema and 233 
depression/anxiety (BMI; smoking; harmful alcohol and high-dose oral glucocorticoid 234 
use) in a third model. To preserve matching, analyses only included valid matched 235 
sets; i.e. entire matched sets were excluded if the atopic eczema exposed individual 236 
was excluded (due to pre-existing outcome diagnosis at cohort entry, or due to 237 
missing BMI or smoking data in the models including possible mediators of the 238 
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relationship between atopic eczema and depression/anxiety), or if no individuals 239 
without atopic eczema remained in the set.  240 
The absolute incidence rates of new depression and anxiety could be directly 241 
calculated among those with atopic eczema, but matching precluded a similar 242 
approach in those without atopic eczema (as this was not a representative sample of 243 
the general population). We, therefore, estimated incidence rates in those without 244 
atopic eczema by multiplying rates in those with atopic eczema by the corresponding 245 
estimated hazard ratio (after inverting it to compare unexposed with exposed).49 We 246 
calculated attributable risks as the difference between the incidence rates in those 247 
with and without atopic eczema, and the population attributable risks by using the 248 
estimated hazard ratio and assuming the prevalence of atopic eczema to be 10%.50  249 
We conducted a series of sensitivity analyses to explore possible sources of bias 250 
introduced by: strict definitions of the psychiatric diagnoses; use of a ‘mixed’ incident 251 
and prevalent cohort; differential practice attendance; or restrictive algorithm-based 252 
definitions of atopic eczema (Table E3). 253 
In pre-specified secondary analyses, we: 1) redefined atopic eczema exposure using 254 
atopic eczema severity as a time-updated variable and compared incidence rates of 255 
depression and anxiety in those with mild, moderate or severe atopic eczema to 256 
those with no atopic eczema; and 2) explored possible effect modification of the 257 
relationship between atopic eczema and depression/anxiety by age, sex and 258 
calendar period.  259 
We checked the proportional hazards assumption for the main analysis models 260 
through visual inspection of Schöenfeld residual plots. All p-values reported are 261 
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based on likelihood-ratio tests, with 99%.51 Statistical analysis was performed using 262 
Stata, version 15.1 (StataCorp LP, College Station, Texas). 263 
RESULTS 264 
Baseline characteristics 265 
We identified 3,095,838 adults aged 18 years or older, including 526,808 with atopic 266 
eczema, and matched them to 2,569,030 without (Figure 1). Further exclusions of 267 
individuals with relevant pre-existing psychiatric diagnoses on or before the start of 268 
follow up yielded 2,467,791 participants in the cohort for analyses with depression as 269 
the outcome, and 2,650,629 with anxiety as the outcome (all belonging to ‘valid sets’, 270 
i.e. matched sets with at least one exposed and one unexposed individual). Median 271 
follow-up was similar in both cohorts: 4.7 (interquartile range [IQR] 1.6-8.6) years for 272 
individuals with atopic eczema and 4.2 (IQR 1.9-9.1) for those without atopic eczema 273 
(Table 1). The mean age of the atopic eczema exposed individuals was 43.9 years 274 
(standard deviation [SD] ±21.7) in the depression cohort and 44.1 (SD±21.43) in the 275 
anxiety cohort. 276 
Participants with atopic eczema were less likely to have missing BMI values or 277 
smoking status, compared to those without atopic eczema, and those with missing 278 
information were more likely to be young and male (Tables E4 and E5). 279 
Main analysis 280 
We explored diagnoses compatible with unipolar depression, GAD, and panic 281 
disorders as the primary outcomes. There was a 1.14-fold (99%CI 1.12-1.16) 282 
increase in the HR for depression in those with atopic eczema compared to those 283 
without, after adjusting for age, sex, general practice, current calendar period and 284 
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IMD at cohort entry (Table 2. Full model Table E6). Atopic eczema was also 285 
associated with a 1.17-fold (99%CI 1.14-1.19) increase in the risk of anxiety. Both 286 
estimates were attenuated after additionally adjusting for BMI, smoking status, 287 
harmful alcohol use, and high-dose corticosteroid use (variables that may mediate 288 
the relationship between atopic eczema and depression/anxiety) (depression: HR 289 
1.10 [99%CI 1.10-1.12]; anxiety: HR 1.12 [99%CI 1.10-1.15]). The absolute excess 290 
risk of depression/anxiety among those with atopic eczema that could be considered 291 
due to atopic eczema (attributable risk) was 160 per 100,000 person-years with 292 
atopic eczema (99%CI 146-186) for depression, and 144 per 100,000 for anxiety 293 
(115-153). While the excess risk of depression/anxiety in the population that could 294 
be considered due to atopic eczema (population attributable risk) was 1.4% (95%CI 295 
1.2-1.6) for depression, and 1.7% (1.4-1.9) for anxiety (Table E7) (these estimates 296 
were calculated assuming a 10% prevalence of atopic eczema and would increase if 297 
atopic eczema were more common). 298 
Our sensitivity analyses showed broadly similar effect estimates-those from the main 299 
analysis (Table E3). 300 
Secondary analyses 301 
Atopic eczema severity 302 
 Regardless of atopic eczema severity level, we saw evidence for an association 303 
between atopic eczema and both depression and anxiety (Figure 2). Compared to 304 
those without atopic eczema, the risk of depression increased with increasing atopic 305 
eczema severity (P<0.0001 for linearity; P=0.3832 for departure from linearity in the 306 
adjusted model, and P=0.6983 for departure from linearity in the model additionally 307 
adjusted for potential mediators). However, the results of analyses exploring the 308 
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relationship between atopic eczema severity and anxiety did not demonstrate a 309 
similarly clear dose-response relationship; for mild and moderate atopic eczema 310 
there was some evidence of a similar dose-response increase, but there was strong 311 
statistical evidence for departure from linearity (P<0.0001) (Table E8). 312 
Effect modification by sex, age and calendar period 313 
We saw some evidence (P<0.0001) for sex modifying the effect of atopic eczema on 314 
depression; with a slightly higher risk of depression in those with atopic eczema 315 
compared to those without in men (1.19 [99%CI 1.16-1.23]) than in women (1.11 316 
[99%CI 1.08-1.13]). We saw a similar pattern for risk of anxiety in those with and 317 
without atopic eczema after stratifying on sex (HR [99% CI): Men 1.22 [99%CI 1.17-318 
1.27]; women 1.14 [99%CI 1.11-1.17]. P=0.0003 for interaction). We also saw 319 
evidence for effect modification by current age, with the HR comparing those with 320 
atopic eczema to those without for both depression (P<0.0001) and anxiety 321 
(P=0.0052) being higher in those aged 40-59, compared to younger and older age 322 
groups. There was no evidence of a change in the effect of atopic eczema on both 323 
depression (p=0.3229) and anxiety (p=0.287) in different calendar periods (Table 324 
E9). 325 
DISCUSSION 326 
Main findings 327 
We found that (treated) atopic eczema was associated with a 14% increase in the 328 
risk of newly diagnosed depression (adjusted HR 99%CI 1.12-1.16), and a 17% 329 
increase in the risk of a subsequent anxiety diagnosis (adjusted HR 99%CI 1.14-330 
1.19). These associations were only slightly attenuated after further adjusting for 331 
potential mediators of the association between atopic eczema and 332 
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anxiety/depression (BMI, smoking status, and alcohol and high-dose corticosteroid 333 
use) and were present at all levels of atopic eczema disease severity. Risk of a new 334 
depression diagnosis increased linearly with increasing atopic eczema severity, 335 
providing strong evidence for a dose-response association. The outcomes were 336 
diagnoses compatible with unipolar depression, GAD, and panic disorders, but we 337 
considered broader definitions of depression/anxiety in subsequent sensitivity 338 
analyses. 339 
Strengths and limitations 340 
We identified a large, nationally-representative sample of people, the largest 341 
reported to-date,20,21 assuring precise effect estimations, and increased 342 
generalisability. We used a validated diagnostic algorithm to identify atopic eczema 343 
in primary care,52 and relied on highly-specific physician-diagnoses rather than self-344 
reported outcomes.53–55 We chose the covariates included in the analysis based on a 345 
priori reasoning (Text E3, Figure E2).48 While some chronic conditions may be 346 
associated with atopic eczema,56 as well as with depression/anxiety,57 in the context 347 
of this study, we did not consider these conditions fit the definition for confounding 348 
because the potential confounder (chronic comorbidity) could be considered to be 349 
either a consequence of the outcome (anxiety/depression), or to mediate the 350 
relationship between exposure and outcome (Text E3).  351 
We deemed other factors (i.e. BMI, smoking, systemic glucocorticoids, harmful 352 
alcohol use) as likely mediators of the effect of atopic eczema on depression and 353 
anxiety, rather than confounders; we consequently adjusted for these variables 354 
separately. Atopic eczema may be associated with the later development of 355 
conditions such as cardiovascular disease and various malignancies,49,56 but 356 
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exploring the potential mediating role of chronic comorbidity was beyond the scope 357 
of our analysis. 358 
The study also has several limitations. The algorithm we used to define atopic 359 
eczema excluded untreated individuals, reducing its sensitivity to detect milder 360 
cases.58 This limitation was mitigated by the availability of primary care data, as 97% 361 
of those with atopic eczema in the UK are managed in primary care,59,60 and by 362 
including emollients, which are routinely prescribed for atopic eczema in the UK.61 363 
The results also remained robust in sensitivity analyses using less restrictive atopic 364 
eczema definitions. Analyses stratified by atopic eczema severity provided further 365 
reassuring evidence of an association between atopic eczema and 366 
anxiety/depression even among mild cases. However, our definition of atopic 367 
eczema severity might have misclassified individuals with severe atopic eczema as 368 
having less severe disease if they refused medical therapy.62 Misclassification of 369 
disease status or severity may have over- or under-estimated the real association 370 
between severity of eczema and anxiety/depression, since early symptoms of 371 
depression/anxiety could influence diagnostic and treatment preferences. However, 372 
GPs recorded their depression/anxiety diagnoses independently and prospectively, 373 
so reverse causality likely affected all study participants equally regardless of atopic 374 
eczema status (i.e. non-differential misclassification, suggesting bias towards the null 375 
rather than a spurious association).  376 
A further limitation of our eczema severity definition was that we were unable to 377 
capture symptom reduction or resolution (absence of a record for eczema does not 378 
necessarily mean absence in symptoms). Consequently, we considered individuals 379 
as having moderate or severe disease from the date they met the respective 380 
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definition, and may therefore have wrongly classified people as having 381 
moderate/severe eczema when their symptoms had reduced or resolved. The result 382 
of wrongly classifying individuals as having more severe disease when their 383 
symptoms had actually remitted would only be to dilute the effect of eczema severity 384 
on depression/anxiety and bias our effect estimate to null. 385 
Follow-up began in adulthood, resulting in a mixed cohort of prevalent and incident 386 
(newly diagnosed) atopic eczema cases, introducing possible bias due to left 387 
truncation (i.e. the possibility of an outcome event occurring before cohort entry), 388 
with consequent under or overestimation of the effect of atopic eczema on 389 
depression and anxiety. However, following only incident cases when exploring 390 
predominantly adult-onset outcomes would have shortened follow-up and limited the 391 
study’s power. Additionally, the exact onset date of a relapsing condition such as 392 
atopic eczema cannot be captured accurately in routinely-collected data; In such 393 
circumstances, a dynamic cohort including prevalent cases is preferred.63 A 394 
sensitivity analysis offered evidence against bias introduced by including both 395 
‘incident’ and prevalent atopic eczema cases in our cohort; as it showed broadly 396 
similar results in those with prevalent atopic eczema, and those more likely to have 397 
new-onset atopic eczema. 398 
Smoking status and/or BMI were not recorded for some study participants, and it is 399 
likely that whether smoking status/BMI were recorded or not of was dependent on 400 
having atopic eczema or anxiety/depression (i.e. missing not-at-random). BMI and 401 
smoking status are often captured opportunistically and are therefore more likely to 402 
be recorded in those who consult their GP more frequently (due to health-seeking 403 
behaviour or chronic conditions).64 While previous studies suggested no clear-cut 404 
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association between physical illness and detection of psychiatric diagnoses in 405 
primary-care,65,66  the possibility of selection bias when applying complete case 406 
analysis (i.e. including only those with complete data) remains. In our study, this did 407 
not affect the main analysis, as the variables containing missing data were not 408 
included in the main adjusted analysis (they were considered as potential 409 
mediators). Comparable results from the model including smoking and BMI, also 410 
provide evidence against substantial bias introduced by missing data. Finally, GPs 411 
do not routinely record patients’ quality of sleep, and we were not able to assess the 412 
extent to which itch-related sleep disturbances mediate the development of 413 
depression and anxiety among people with atopic eczema.30 414 
Comparisons to existing literature 415 
An association between atopic eczema, depression and anxiety has been described 416 
in cross-sectional and case-control studies, in which the temporal sequence (i.e. 417 
whether atopic eczema precedes depression or anxiety, or vice versa) could not be 418 
determined.16–22 The few longitudinal studies that addressed this question had 419 
inconsistent results.32–34 These studies were limited by short follow-up windows;34 420 
inclusion of selected, non-representative populations (e.g. male military conscripts,34 421 
or secondary-care diagnoses 32,33); no account of atopic eczema disease 422 
severity;32,34 low-quality or no individual-level information on lifestyle variables;32,34 423 
and reliance on disease-specific medication usage as a non-specific proxy measure 424 
to ascertain depression and anxiety.33,34 Notably, a recent Danish cohort study 425 
demonstrated point-estimates that were in-line with the estimates reported in our 426 
study, but the association was not evident in the adjusted models that included 427 
healthcare consumption.33  428 
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Interpretation and clinical implications 429 
Atopic eczema, like several other chronic conditions,57 is associated with 430 
depression/anxiety. The link to chronic mental illness further supports the view of 431 
atopic eczema as a systemic disorder.67 Our results suggest that the association 432 
between atopic eczema and depression/anxiety is not substantially mediated through 433 
glucocorticoid treatment, obesity, smoking, or harmful alcohol intake. Evidence 434 
against a dose-response association between atopic eczema severity and anxiety 435 
could imply different pathophysiological mechanisms, but could also reflect 436 
misclassification of outcome, as the anxiety outcome was more heterogeneously 437 
defined. Our findings suggest that atopic eczema was more strongly associated with 438 
depression and anxiety in those aged 40-59 (compared to younger and older age 439 
groups). However, it is unclear why; further research could investigate possible 440 
explanations for differences in the association between atopic eczema and 441 
depression/anxiety risk in those at different ages (for example, different age-specific 442 
coping strategies, or increased health care contacts due to active cardiovascular 443 
screening in that age group). Future research could also support our findings of a 444 
dose-response association between atopic eczema and depression/anxiety by 445 
including people with more severe forms of these conditions (e.g. identified using 446 
prescriptions for antidepressants and anxiolytic medications). 447 
While our results apply directly to UK primary care, they are likely to be relevant in 448 
other settings, especially where there is primary care-oriented universal access to 449 
healthcare. Mental illness is underdiagnosed in people with skin or other chronic 450 
diseases,68–70 but their detection and treatment might improve atopic eczema control 451 
by facilitating better adherence to skin disease treatment,71 or through direct anti-452 
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inflammatory actions of antidepressants.72 Current UK guidelines address only the 453 
management of atopic eczema in children, emphasising the importance of assessing 454 
the psycho-social well-being and quality of life.73 Recent guidelines from the 455 
European Academy of Dermatology and Venereology comment briefly on the 456 
influence of psychological and emotional factors on the clinical course of atopic 457 
eczema.5 Neither of these guidelines mentions the long-term mental-health 458 
implications of atopic eczema. Our findings suggest that depression and anxiety 459 
should be addressed explicitly in future guideline updates. Further research is 460 
needed to explore and define possible mediators; to characterise subpopulations at 461 
increased risk (e.g. those with adult-onset atopic eczema, or those with more active 462 
variants of the disease); and to elucidate the feasibility and effectiveness of 463 
screening, early detection and prevention of depression and anxiety among those 464 
with atopic eczema. 465 
Conclusions 466 
Individuals affected with atopic eczema were more likely to develop depression and 467 
anxiety, regardless of atopic eczema severity. Strong evidence for a dose-response 468 
relationship between atopic eczema severity and depression supports a causal 469 
association. These results highlight the importance of a comprehensive bio-psycho-470 
social approach to limit common mental disorders in those with atopic eczema and 471 
could guide recommendations for the management of atopic eczema.   472 
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FIGURES 763 
Figure 1. Flow diagram showing the creation of the cohort and reasons for 764 
exclusion (1998-2016) 765 
 766 
Abbreviations: CPRD, Clinical Practice Research Datalink; HES, hospital episode statistics UTS, up-767 
to-standard  768 
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Depression cohort
Anxiety cohort  (n= 2,254,338)
• Exposed (n=426,430)
• Unexposed (n=1,827,908)
Individuals with a code suggesting a 
pre-existing diagnosis (i.e. core 
diagnostic codes, symptoms, ‘non-
definitive’, alternative diagnosis or 
any history code)
• Eczema cases (n=99,068)
• Unexposed (346,141)
n=2,650,629
Eczema cases without a 
remaining match 
(n=1,310)
Unexposed excluded due 
to no remaining index 
case in set (n=394,981)
Anxiety cohort
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Figure 2. Hazard ratios (99%CI) for the association between eczema severity 769 
(time-updated) and depression and anxiety. 770 
* compared to no atopic eczema 771 
Abbreviations: BMI, body mass index; IMD, index of multiple deprivation. 772 
All models were fitted to people with complete data for all included variables. Sets without at least one 773 
exposed and one unexposed were excluded. Hazard ratios were estimated from a Cox regression 774 
model with current age as the underlying time scale, stratified by matched set (sex, age and general 775 
practice).  776 
A minimally adjusted model accounted for the matching variables (1,980,710 participants in the 777 
depression cohort [1,920,172 unique people], and 2,242,905 in the anxiety cohort [2,171,784 unique 778 
people]).  779 
The adjusted model additionally included current calendar period (years: 1998-2001, 2002-06, 2007-780 
11, 2012 16,) and quintiles of IMD at cohort entry (same participants as in the minimally adjusted).  781 
A final model, additionally adjusted for potential mediators included also BMI (categorised as 782 
normal, 18.5-24 kg/m2; underweight, <18.5 kg/m2; overweight 25-29 kg/m2; obese ≥30 kg/m2) 783 
smoking status, and alcohol and high-dose corticosteroid use (≥20 mg/day prednisolone equivalent 784 
dose), both as time updated variables (1,371,005 participants in the depression cohort [1,322,284 785 
unique people], and 1,583,390 in the anxiety cohort [1,583,390 unique people]). 786 
a. Depression - P-values were <0.0001 for linearity in all models, and for departure from linearity 787 
were: minimally adjusted p=0.3810; adjusted p=0.3832; and additionally adjusted for potential 788 
mediators p=0.6983. 789 
b. Anxiety - P-values were <0.0001 for linearity in all models, and <0.0001 for departure from linearity 790 
in all models.  791 
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Hazard ratio
(99% CI)
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Adjusted
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TABLES 792 
Table 1. Characteristics of people with and without atopic eczema at cohort 793 
entry for both depression and anxiety cohorts. 794 
 Depression cohort Anxiety cohort 
Characteristic* 
Without atopic 
eczema 
n=1,588,277 
With atopic 
eczema 
n=392,433 
Without atopic 
eczema 
n=1,827,908 
With atopic 
eczema 
n=426,430 
Follow-up (years), 
median (IQR) 
4.21 (1.63-8.62) 4.72 (1.86-9.12) 4.18 (1.62-8.6) 4.71 (1.85-9.13) 
Female sex 802,909 (50.6%) 211,118 (53.8%) 981,824 (53.1%) 237,527 (55.7%) 
Age (years)     
18-39 828,072 (52.1%) 195,455 (49.8%) 941,183 (51.5%) 210,764 (49.4%) 
40-59 355,209 (22.4%) 89,126 (22.7%) 431,329 (23.6%) 100,592 (23.6%) 
≥60 404,996 (25.5%) 107,852 (27.5%) 455,396 (24.9%) 115,074 (27.0%) 
Index of multiple 
deprivation (quintiles) 
    
1 (least deprived) 395,025 (24.9%) 99,161 (25.3%) 443,389 (24.3%) 104,672 (24.6%) 
2 368,687 (23.2%) 91,856 (23.4%) 419,555 (23.0%) 98,500 (23.1%) 
3 311,975 (19.6%) 76,756 (19.6%) 360,901 (19.7%) 84,121 (19.7%) 
4 295,103 (18.6%) 72,538 (18.5%) 346,152 (18.9%) 80,198 (18.8%) 
5 (most deprived) 217,487 (13.7%) 52,122 (13.3%) 257,911 (14.1%) 58,939 (13.8%) 
Body mass index 
(kg/m2), mean (SD) 
25.74 (5.1) 26.01 (5.3) 25.87 (5.2) 26.18 (5.4) 
Normal (18.5-24 kg/m2) 574,056 (36.1%) 147,216 (37.5%) 663,955 (36.3%) 158,315 (37.1%) 
Underweight (<18.5 
kg/m2) 
40,118 (2.5%) 9,830 (2.5%) 46,346 (2.5%) 10,536 (2.5%) 
Overweight (25-29 kg/m2) 397,525 (25.0%) 105,468 (26.9%) 460,537 (25.2%) 114,921 (27.0%) 
Obese (≥30 kg/m2) 209,823 (13.2%) 60,643 (15.5%) 258,799 (14.2%) 70,714 (15.6%) 
Missing 366,755 (23.1%) 69,276 (17.7%) 398,271 (21.8%) 71,944 (16.9%) 
Smoking status     
Non-smoker 833,152 (52.5%) 211,240 (53.8%) 939,278 (51.4%) 222,529 (52.2%) 
Current/ex-smoker 638,023 (40.2%) 168,778 (43.0%) 763,295 (41.8%) 191,066 (44.8%) 
Missing 117,102 (7.4%) 12,415 (3.2%) 125,335 (6.9%) 12,835 (3.0%) 
Harmful alcohol use 23,244 (1.5%) 7,114 (1.8%) 31,639 (1.7%) 9,119 (2.1%) 
High-dose 
glucocorticoids (>=20 
mg/day prednisolone 
equivalent dose)  
65,155 (4.1%) 42,738 (10.9%) 78,579 (4.3%) 47,840 (11.2%) 
Abbreviations: IQR, interquartile range; SD, standard deviation. 795 
* See Text E4 for details of variable definitions.796 
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Table 2. Hazard ratios (99% CI) from Cox regression for the association between atopic eczema and anxiety and 797 
depression. 798 
   Minimally adjusted* Adjusted** Additionally adjusted for potential mediators*** 
 No. 
Events/PYAR 
Hazard Ratio 
(99% CI) 
Hazard Ratio 
(99% CI) No. Events/PYAR 
Hazard Ratio 
(99% CI) 
Depression 
No atopic eczema  1,588,277 102,882/8,935,934 1.00 (ref) 1.00 (ref) 1,054,673 76,638/6,531,745 1.00 (ref) 
Atopic eczema 392,433 31,322/2,354,118 1.14 (1.12-1.16) 1.14 (1.12-1.16) 316,332 27,405/2,042,715 1.10 (1.07-1.12) 
Anxiety 
No atopic eczema  1,818,796 82,137/10,187,499 1.00 (ref) 1.00 (ref) 1,237,423 63,592/7,566,056 1.00 (ref) 
Atopic eczema 424,109 24,283/2,543,384 1.17 (1.14-1.19) 1.17 (1.14-1.19) 345,967 21,666/2,223,508 1.12 (1.09-1.15) 
 
Abbreviations: BMI, body mass index; IMD, index of multiple deprivation; CI, confidence interval; PYAR, person years at risk. 799 
All models were fitted to people with complete data for all included variables. Matched sets without at least one individual with atopic eczema and one without 800 
were excluded. Hazard ratios were estimated from a Cox regression model with current age as the underlying time scale, stratified by matched set (sex, age 801 
and general practice). 802 
*Minimally-adjusted model accounted for the matching variables (1,980,710 participants in the depression cohort [1,920,172 unique people], and 2,242,905 803 
in the anxiety cohort [2,171,784 unique people]).  804 
**The adjusted model additionally included current calendar period (years: 1998-2001, 2002-06, 2007-11, 2012-16) and quintiles of IMD at cohort entry 805 
(same participants as in the minimally adjusted).  806 
***Additionally adjusted for potential mediators: BMI (categorised as normal, 18.5-24 kg/m2; underweight, <18.5 kg/m2; overweight 25-29 kg/m2; obese 807 
≥30 kg/m2) smoking status, and alcohol and high-dose corticosteroid use (≥20 mg/day prednisolone equivalent dose), both as time updated variables 808 
(1,371,005 participants in the depression cohort [1,322,284 unique people], and 1,583,390 in the anxiety cohort [1,583,390 unique people]). 809 
